Cercar

01/09/2023 Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients
Mazuecos, A, Villanego, F, Alonso, A, Beneyto, I, Crespo, M, Diaz-Corte, C, Franco, A, Gonzalez-Roncero, F, Guirado, L, Jimenez, C, Juega, J, Llorente, S, Paul, J, Rodriguez-Benot, A, Ruiz, JC, Sanchez-Fructuoso, A, Torregrosa, V, Rodrigo, E, Hernandez, D, Lopez, V, Lopez-Oliva, M, Zarraga, S. Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients. NEFROLOGIA. 2023; 43(5)DOI:10.1016/j.nefro.2022.11.001. PMID:37957107. IF:2.000(Q2/5D).
01/08/2023 Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy
Sevillano, AM, Caravaca-Fontan, F, Garcia-Galan, LC, Fernandez-Juarez, G, Lopez-Revuelta, K, Guzman, DA, Martin-Reyes, G, Quintana, LF, Rodas, LM, de la Nieta, MDS, Rabasco, C, Espinosa, M, Diaz-Encarnacion, M, San Miguel, L, Barrios, C, Rodriguez, E, Garcia, P, Valera, A, Pena, JK, Shabaka, A, Velo, M, Sierra, M, Gonzalez, F, Fernandez-Reyes, MJ, Heras, M, Delgado, P, Gutierrez, E, Moreno, JA, Praga, M. Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy. Kidney International Reports. 2023; 8(8)DOI:10.1016/j.ekir.2023.05.027. PMID:37547537. IF:5.700(Q1/1D).
19/06/2023 Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy
Kiryluk, K, Sanchez-Rodriguez, E, Zhou, XJ, Zanoni, F, Liu, LL, Mladkova, N, Khan, A, Marasa, M, Zhang, JY, Balderes, O, Sanna-Cherchi, S, Bomback, AS, Canetta, PA, Appel, GB, Radhakrishnan, J, Trimarchi, H, Sprangers, B, Cattran, DC, Reich, H, Pei, YR, Ravani, P, Galesic, K, Maixnerova, D, Tesar, V, Stengel, B, Metzger, M, Canaud, G, Maillard, N, Berthoux, F, Berthelot, L, Pillebout, E, Monteiro, R, Nelson, R, Wyatt, RJ, Smoyer, W, Mahan, J, Samhar, A, Hidalgo, G, Quiroga, A, Weng, PTC, Sreedharan, R, Selewski, D, Davis, K, Kallash, M, Vasylyeva, TL, Rheault, M, Chishti, A, Ranch, D, Wenderfer, SE, Samsonov, D, Claes, DJ, Akchurin, O, Goumenos, D, Stangou, M, Nagy, J, Kovacs, T, Fiaccadori, E, Amoroso, A, Barlassina, C, Cusi, D, Del Vecchio, L, Battaglia, GG, Bodria, M, Boer, E, Bono, L, Boscutti, G, Caridi, G, Lugani, F, Ghiggeri, G, Coppo, R, Peruzzi, L, Esposito, V, Esposito, C, Feriozzi, S, Polci, R, Frasca, G, Galliani, M, Garozzo, M, Mitrotti, A, Gesualdo, L, Granata, S, Zaza, G, Londrino, F, Magistroni, R, Pisani, I, Magnano, A, Marcantoni, C, Messa, P, Mignani, R, Pani, A, Ponticelli, C, Roccatello, D, Salvadori, M, Salvi, E, Santoro, D, Gembillo, G, Savoldi, S, Spotti, D, Zamboli, P, Izzi, C, Alberici, F, Delbarba, E, Florczak, M, Krata, N, Mucha, K, Paczek, L, Niemczyk, S, Moszczuk, B, Panczyk-Tomaszewska, M, Mizerska-Wasiak, M, Perkowska-Ptasinska, A, Baczkowska, T, Durlik, M, Pawlaczyk, K, Sikora, P, Zaniew, M, Kaminska, D, Krajewska, M, Kuzmiuk-Glembin, I, Heleniak, Z, Bullo-Piontecka, B, Liberek, T, Debska-Slizien, A, Hryszko, T, Materna-Kiryluk, A, Miklaszewska, M, Szczepanska, M, Dyga, K, Machura, E, Siniewicz-Luzenczyk, K, Pawlak-Bratkowska, M, Tkaczyk, M, Runowski, D, Kwella, N, Drozdz, D, Habura, I, Kronenberg, F, Prikhodina, L, van Heel, D, Fontaine, B, Cotsapas, C, Wijmenga, C, Franke, A, Annese, V, Gregersen, PK, Parameswaran, S, Weirauch, M, Kottyan, L, Harley, JB, Suzuki, H, Narita, I, Goto, S, Lee, HJ, Kim, DK, Kim, YS, Park, JH, Cho, BL, Choi, M, Van Wijk, A, Huerta, A, Ars, E, Ballarin, J, Lundberg, S, Vogt, B, Mani, LY, Caliskan, Y, Barratt, J, Abeygunaratne, T, Kalra, PA, Gale, DP, Panzer, U, Rauen, T, Floege, J, Schlosser, P, Ekici, AB, Eckardt, KU, Chen, N, Xie, JY, Lifton, RP, Loos, RJF, Kenny, EE, Ionita-Laza, I, Kottgen, A, Julian, BA, Novak, J, Scolari, F, Zhang, H, Gharavi, AG. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. NATURE GENETICS. 2023; 55(7)DOI:10.1038/s41588-023-01422-x. PMID:37337107. IF:31.800(Q1/1D).
27/05/2023 Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration
de Sequera, P, Perez-Garcia, R, Vega, A, Martinez-Vaquera, S, Acosta, JG, Del Valle, KP, Fernandez-Lucas, M, Garcia-Rubiales, MA, Garcia-Herrera, AL, Coll, E, Merida, E, Martinez-Miguel, P, Castano, I, Gil-Casares, B, Garro, J, Maduel, F. Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration. Clinical Kidney Journal. 2023; 16(11)DOI:10.1093/ckj/sfad128. PMID:37915938. IF:3.900(Q1/2D).
01/05/2023 'The forgotten sex': gender disparities in kidney disease
Stevens, KI, Mallamaci, F, Ortiz, A, Bover, J, Delanaye, P, Torra, R, Cozzolino, M. 'The forgotten sex': gender disparities in kidney disease. Clinical Kidney Journal. 2023; 17(4)DOI:10.1093/ckj/sfad102. PMID:38628911. IF:3.900(Q1/2D).
20/02/2023 Expanded hemodialysis: what's up, Doc?
Garcia-Prieto, A, de la Flor, JC, Coll, E, Iglesias, E, Reque, J, Valga, F. Expanded hemodialysis: what's up, Doc?. Clinical Kidney Journal. 2023; 16(7)DOI:10.1093/ckj/sfad033. PMID:37398691. IF:3.900(Q1/2D).
01/01/2023 Renal involvement in rare genetic diseases
Doyágüez P.R., Boldoba N.B., Gimena R., Sevillano B.H., Ballcells R.T.. Renal involvement in rare genetic diseases. Medicine (spain). 2023; 13(79)DOI:10.1016/j.med.2023.05.004. PMID:. IF:(Q/D).
01/01/2023 Correlación de la inactivación del cromosoma X con la presentación clínica de la enfermedad de Fabry a propósito de un caso
Rodríguez Doyágüez P., Furlano M., Ars Criach E., Arce Y., Guirado L., Torra Balcells R.. Correlación de la inactivación del cromosoma X con la presentación clínica de la enfermedad de Fabry a propósito de un caso. NEFROLOGIA. 2023; 43DOI:10.1016/j.nefro.2022.12.001. PMID:. IF:(Q/D).
01/01/2023 Why do we keep ignoring sex in kidney disease?
Jankowska M., JoséSoler M., Stevens K.I., Torra R.. Why do we keep ignoring sex in kidney disease?. Clinical Kidney Journal. 2023; 16(12)DOI:10.1093/ckj/sfad183. PMID:. IF:(Q/D).
01/01/2023 Artificial intelligence: a new field of knowledge for nephrologists
De Arizón L.F., Viera E.R., Pilco M., Perera A., De Maeztu G., Nicolau A., Furlano M., Torra R.. Artificial intelligence: a new field of knowledge for nephrologists. Clinical Kidney Journal. 2023; 16(12)DOI:10.1093/ckj/sfad182. PMID:. IF:(Q/D).
01/12/2025 Re: Angiogenic factors alone or in combination with ultrasound Doppler criteria for risk classification among late-onset small fetuses with or without pre-eclampsia
Mendoza, M, Garcia-Manau, P, Bonacina, E, Maiz, N. Re: Angiogenic factors alone or in combination with ultrasound Doppler criteria for risk classification among late-onset small fetuses with or without pre-eclampsia. ULTRASOUND IN OBSTETRICS & GYNECOLOGY. 2025; 66(6)DOI:10.1002/uog.70021. PMID:40878378. IF:6.300(Q1/1D).
17/10/2025 DNA Damage and Bisphenol Levels in Chronic Kidney Disease Patients Undergoing Hemodialysis
Ruiz, CE, Vela, L, Nadal, M, González, N, Marcos, R, Hernández, A, Pastor, S, Coll, E. DNA Damage and Bisphenol Levels in Chronic Kidney Disease Patients Undergoing Hemodialysis. Journal Of Xenobiotics. 2025; 15(5)DOI:10.3390/jox15050167. PMID:41149753. IF:(Q/D).
01/10/2025 Effect of bisphenols on genomic damage in patients with chronic kidney disease on hemodialysis
Garcia, CR, Pastor, S, Gali, AR, Benito, S, El Bachouti, J, Garcia, MAH, Piera, EC. Effect of bisphenols on genomic damage in patients with chronic kidney disease on hemodialysis. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.0769. PMID:. IF:5.600(Q1/1D).
01/10/2025 Recurrence of focal segmental glomerulosclerosis after kidney transplantation: over 40 years of experience in our centre
Guasch, AD, de Arizón, LF, Saltos, JJA, El Bachouti, J, Canal, C, Cordoba, C, Perez, M, Perich, LG, Molas, CF, Cabanas, NS. Recurrence of focal segmental glomerulosclerosis after kidney transplantation: over 40 years of experience in our centre. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.1885. PMID:. IF:5.600(Q1/1D).
01/10/2025 Impact of phase angle on mortality in hemodialysis patients
Delgado, AB, Piera, EC, El Bachouti, J, Zules, RG, Perich, LG, Gali, AR, Benito, S, Ruiz, C. Impact of phase angle on mortality in hemodialysis patients. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.076. PMID:. IF:5.600(Q1/1D).
01/10/2025 CD163+macrophages: a prognostic marker in ANCA vasculitis?
Benito-García, S, Bardaji, B, Arce, Y, Moya, P, Freiria, XB, Marco, H, Perich, LG, Encarnacion, MMD. CD163+macrophages: a prognostic marker in ANCA vasculitis?. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.0218. PMID:. IF:5.600(Q1/1D).
01/10/2025 Leveraging AI for early detection of chronic kidney and hereditary kidney diseases: a focus on Alport syndrome
Ramírez, ERV, de Maeztu, G, de Arizón, LF, Teran, MP, Torra, R. Leveraging AI for early detection of chronic kidney and hereditary kidney diseases: a focus on Alport syndrome. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.1061. PMID:. IF:5.600(Q1/1D).
01/10/2025 Is living kidney donation with expanded criteria safe for the donor? long-term follow-up from the Catalan Registry
Perich, RA, Perich, LG, Perez, M, Tort, J, Revuelta, I, Manonelles, A, Molas, CF, Moreso, FJ, Crespo, M, Cañas, L, Comas, J, Arcos, E. Is living kidney donation with expanded criteria safe for the donor? long-term follow-up from the Catalan Registry. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.108. PMID:. IF:5.600(Q1/1D).
01/10/2025 Increase in the use of expanded criteria living donors to facilitate preemptive kidney transplantation for our patients
Perich, RA, Arcos, E, Comas, J, Cabanas, NS, Tort, J, Revuelta, I, Manonelles, A, Crespo, M, Moreso, FJ, Santandreu, AV, Molas, CF, Perich, LG. Increase in the use of expanded criteria living donors to facilitate preemptive kidney transplantation for our patients. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.0870. PMID:. IF:5.600(Q1/1D).
01/10/2025 Long-term outcomes of renal transplantation from expanded criteria living donors
Perich, RA, Arcos, E, Comas, J, de Arizón, LF, Tort, J, Revuelta, I, Manonelles, A, Crespo, M, Moreso, FJ, Santandreu, AV, Molas, CF, Perich, LG. Long-term outcomes of renal transplantation from expanded criteria living donors. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.0869. PMID:. IF:5.600(Q1/1D).
01/10/2025 First report of kidney failure in PEX6-related peroxisomal disorder
Buia, G, Zanlonghi, X, Audrezet, MP, Zagorec, N, Ars, E, Dhaenens, CM, Odent, S, Cornec-Le Gall, E. First report of kidney failure in PEX6-related peroxisomal disorder. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.1020. PMID:. IF:5.600(Q1/1D).
01/10/2025 Enhancing diagnostic precision for inherited kidney diseases: the importance of databases
de Arizón, LF, Leon, R, Ramírez, ERV, Furlano, M, Arango, P, Báez, VAL, Centers, EE, Perera, A, Torra, R. Enhancing diagnostic precision for inherited kidney diseases: the importance of databases. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.010. PMID:. IF:5.600(Q1/1D).
01/10/2025 Safety and efficacy of SGLT2i in non-diabetic kidney transplant recipients
Robles, CA, Quilis, A, Gómez, PF, López, V, Vigara, LA, Borrás, PGC, Torres-Sánchez, MJ, Canal, C, del Valle, AISS, Cuellar, HT, Fructuoso, AIS, Buxeda, A. Safety and efficacy of SGLT2i in non-diabetic kidney transplant recipients. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.0884. PMID:. IF:5.600(Q1/1D).
01/10/2025 A decade of ABO incompatible kidney transplantation: results and lessons learned
Herrera, CC, Cabanas, NS, Perez, M, de Arizón, LF, Molas, CF, Perich, LG, Perich, RA, Pasache, HK, Garcia, MAH. A decade of ABO incompatible kidney transplantation: results and lessons learned. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.1864. PMID:. IF:5.600(Q1/1D).
01/10/2025 Immunotherapy in kidney transplant patients with cancer: the latest challenge
Cabanas, NS, Cordoba, C, Perez, M, de Arizón, LF, Freiria, XB, Pasache, HK, Guirado, L, Molas, CF. Immunotherapy in kidney transplant patients with cancer: the latest challenge. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.1863. PMID:. IF:5.600(Q1/1D).
02/09/2025 Propofol-based versus sevoflurane-based anaesthesia for deceased donor kidney transplantation: the VAPOR-2 study protocol for an international multicentre randomised controlled trial
Huisman, GJJ, Berger, SP, Thyrrestrup, PS, Hausken, J, Veelo, DP, Guirado, L, Pol, R, Jensen, LL, Tonnessen, TI, Bemelman, FJ, Facundo, C, Tamasi, K, Lunter, G, Jespersen, B, Leuvenink, HGD, Struys, MMRF, Nieuwenhuijs-Moeke, GJ. Propofol-based versus sevoflurane-based anaesthesia for deceased donor kidney transplantation: the VAPOR-2 study protocol for an international multicentre randomised controlled trial. BMJ Open. 2025; 15(9)DOI:10.1136/bmjopen-2025-098965. PMID:40897490. IF:2.300(Q2/3D).
01/09/2025 ABCDE to identify and prevent chronic kidney disease: a call to action
Ferro, CJ, Wanner, C, Luyckx, V, Stevens, K, Cerqueira, S, Darwish, R, Fernandez, BF, Fiel, D, Filev, R, Grieger, M, Lopez, A, Luman, M, Malyszko, J, Nikolova-Vlahova, MK, Romero, F, Skalioti, C, Araujo, CARD, Ziedina, I, Gallego, D, Ortiz, A, Torra, R, Vanholder, R. ABCDE to identify and prevent chronic kidney disease: a call to action. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40(9)DOI:10.1093/ndt/gfaf057. PMID:40107862. IF:5.600(Q1/1D).
21/05/2025 URINARY PROTEOMIC ANALYSIS PROVIDES DIFFERENT PATTERNS BETWEEN LUPUS PATIENTS WITH AND WITHOUT NEPHRITIS: RESULTS OF A MULTICENTER STUDY IN 124 PATIENTS
Lucea, ER, García, NAR, Inchaurbe, A, Alén, JC, Aurrecoechea, E, Sola, AD, Zarrabeitia, LR, Diaz, M, Galindez, E, Fernández, O, Torre, I, Exposito, R, Allande, MJ, Abad-Plou, E, Alvarez, LV, Enjuanes, M, Gonzalez, G, Gonzalez, M, López, L, Barahona, E, Martínez, D, Alvarez, J, García-Vivar, ML. URINARY PROTEOMIC ANALYSIS PROVIDES DIFFERENT PATTERNS BETWEEN LUPUS PATIENTS WITH AND WITHOUT NEPHRITIS: RESULTS OF A MULTICENTER STUDY IN 124 PATIENTS. JOURNAL OF RHEUMATOLOGY. 2025; 52DOI:. PMID:. IF:3.400(Q2/3D).
01/04/2025 N-terminal pro B-type natriuretic peptide as biomarker to predict pre-eclampsia and maternal-fetal complications
Nan, MN, Garrido-Giménez, C, Garcia-Osuna, A, Manau, PG, Ullmo, J, Mora, J, Sanchez-Garcia, O, Platero, J, Cruz-Lemini, M, Llurba, E. N-terminal pro B-type natriuretic peptide as biomarker to predict pre-eclampsia and maternal-fetal complications. ULTRASOUND IN OBSTETRICS & GYNECOLOGY. 2025; 65(4)DOI:10.1002/uog.29202. PMID:40088200. IF:6.300(Q1/1D).
01/12/2024 Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study
de Winter, DP, Lopriore, E, Thorup, E, Petersen, OB, Dziegiel, MH, Sundberg, K, Devlieger, R, de Catte, L, Lewi, L, Debeer, A, Houfflin-Debarge, V, Ghesquiere, L, Garabedian, C, Le Duc, K, Antolin, E, Mendez, N, Castleman, J, Tse, WT, Jouannic, JM, Maurice, P, Currie, J, Mullen, E, Geerts, L, Rademan, K, Khalil, A, Poljak, B, Prasad, S, Tiblad, E, Bohlin, K, Geipel, A, Rath, J, Malone, F, Mackin, D, Yinon, Y, Cohen, S, Ryan, G, Vlachodimitropoulou, E, Gloning, KP, Verlohren, S, Mayer, B, Lanna, M, Faiola, S, Srsen, TP, Cerar, LK, Snowise, S, Sun, LM, Otaño, L, Meller, CH, Connors, NK, Saxonhouse, M, Wolter, A, Bedei, I, Klaritsch, P, Jauch, S, Ribeiro, ETDS, Peixoto, FM, Martinez-Portilla, RJ, Matias, A, Abad, OA, Roca, JP, Grisi, AGA, Navarro, EJJC, van der Bom, JG, de Haas, M, Verweij, EJT. Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study. Lancet Haematology. 2024; 11(12)DOI:10.1016/S2352-3026(24)00314-4. PMID:39527958. IF:17.700(Q1/1D).
01/11/2024 Prenatal exposure to per- and polyfluoroalkyl substances, fetoplacental hemodynamics, and fetal growth
Knox, B, Güil-Oumrait, N, Basagaña, X, Cserbik, D, Dadvand, P, Foraster, M, Galmes, T, Gascon, M, Gomez-Roig, MD, Gomez-Herrera, L, Haug, LS, Llurba, E, Márquez, S, Rivas, I, Sunyer, J, Thomsen, C, Zanini, MJ, Bustamante, M, Vrijheid, M. Prenatal exposure to per- and polyfluoroalkyl substances, fetoplacental hemodynamics, and fetal growth. ENVIRONMENT INTERNATIONAL. 2024; 193DOI:10.1016/j.envint.2024.109090. PMID:39454342. IF:9.700(Q1/1D).
01/09/2024 Functional structure of local connections and differentiation of cerebral cortex areas in the neonate
Pujol, J, Blanco-Hinojo, L, Persavento, C, Martinez-Vilavella, G, Falcon, C, Gascon, M, Rivas, I, Vilanova, M, Deus, J, Gispert, JD, Gomez-Roig, MD, Llurba, E, Dadvand, P, Sunyer, J. Functional structure of local connections and differentiation of cerebral cortex areas in the neonate. NEUROIMAGE. 2024; 298DOI:10.1016/j.neuroimage.2024.120780. PMID:39122060. IF:4.500(Q1/1D).
01/07/2024 Reference Ranges of 2-Dimensional Placental Biometry and 3-Dimensional Placental Volume between 11 and 14 Weeks of Gestation
Solà, CT, Roca, JP, Olivé, EL. Reference Ranges of 2-Dimensional Placental Biometry and 3-Dimensional Placental Volume between 11 and 14 Weeks of Gestation. Diagnostics. 2024; 14(14)DOI:10.3390/diagnostics14141556. PMID:39061694. IF:3.300(Q1/2D).
01/06/2024 Evaluation of 341 patients follow up after primary repair of obstetric anal sphincter injuries (OASI)
Garcia, MP, Hervas, IM, Oliveras, MTM, Montoro, I, Olivé, EL. Evaluation of 341 patients follow up after primary repair of obstetric anal sphincter injuries (OASI). EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024 Can NT-proBNP improve the diagnosis of angiogenic factors for preeclampsia?
Garrido-Gimenez, C, Cruz-Lemini, M, Nan, MN, Mora-Burgues, J, Garcia-Manau, P, Ullmo, U, Sanchez-Garcia, O, Garcia-Osuna, A, Llurba, E. Can NT-proBNP improve the diagnosis of angiogenic factors for preeclampsia?. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024 Fetal left ventricle function evaluated by 2D-STE across clinical stages of severity in growth-restricted foetuses
Dominguez, C, Ginjaume, N, Ullmo, J, Parra, J, Vaquez, A, Cruz-Lemini, M, Llurba, E. Fetal left ventricle function evaluated by 2D-STE across clinical stages of severity in growth-restricted foetuses. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024 Association of microRNA levels with birth outcomes
Ruiz, ZG, García, OS, Olivé, EL, Gómez, MD, Sunyer, J, Dadvand, P, Tomás, MC, Pineda, MB. Association of microRNA levels with birth outcomes. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024 Multicenter study on fixation to the levator ani muscle in laparoscopic colposacropexy. Preliminary results
Hervás, IM. Multicenter study on fixation to the levator ani muscle in laparoscopic colposacropexy. Preliminary results. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024 NT-proBNP as a marker for ruling out preeclampsia
Nan, MN, Garrído-Giménez, C, Mora, J, Ullmo, J, Garcia-Manau, P, Sánchez-García, O, García-Osuna, A, Lemini, MC, Llurba, E. NT-proBNP as a marker for ruling out preeclampsia. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024 Predictive model for preeclampsia combining sFlt-1, PlGF, NT-proBNP and uric acid as biomarkers
Garrido-Gimenez, C, Cruz-Lemini, M, Nan, MN, Mora-Burgues, J, Carretero, F, Alvarez, F, Sanchez-Garcia, O, Garcia-Osuna, A, Llurba, E. Predictive model for preeclampsia combining sFlt-1, PlGF, NT-proBNP and uric acid as biomarkers. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).